Bifidobacterium breve inhibits colorectal cancer via extracellular vesicles containing formate acetyltransferase - PubMed
4 hours ago
- #Probiotics
- #Colorectal Cancer
- #Extracellular Vesicles
- Bifidobacterium breve (B. breve) inhibits colorectal cancer (CRC) via extracellular vesicles (EVs) containing formate acetyltransferase (pflB).
- CRC is the second leading cause of cancer-related mortality worldwide.
- B. breve-derived EVs (B.breEVs) selectively accumulate in tumor tissue, induce apoptosis in CRC cells, and enhance anti-tumor immunity.
- pflB, identified as a key protein in B.breEVs, upregulates granzyme B, perforin1, and activates the intrinsic apoptotic pathway.
- Combination therapy of pflB with anti-PD1 enhances CD8+ cytotoxic T lymphocytes (CTLs) and NK cell infiltration and cytotoxicity.
- B. breve and its EVs reshape intestinal micro-ecology and offer a novel probiotic-EVs-protein intervention strategy for CRC.